Gene therapy for HIV infections: Intracellular immunization

Canadian Journal of Infectious Diseases

Volumn 10, Issue 4, 1999, Pages 307-312

  Piché, Alain ^a,b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Gene therapy; Human immunodeficiency virus (HIV); Intracellular immunization

Indexed keywords

ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; RIBOZYME;

CLINICAL TRIAL; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; REVIEW; VIRUS INACTIVATION; VIRUS REPLICATION;

EID: 0032843345     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/914379     Document Type: Review

References (46)

1. Baltimore D. Gene therapy: intracellular immunization. Nature 1988;335:395-6.
2. Chen SY, Bagley J, Marasco WA. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther 1994;5:595-601.
3. Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 1993;90:7889-93.
4. Chen SY, Khouri Y, Bagley J, Marasco WA. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci USA 1994;91:5932-6.
5. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 1995;14:1542-51.
6. Poznansky MC, Foxcall U, Ramstedt R, et al. Intracellular antibodies against Tat and gp120 inhibit the replication of HIV-1 in T-cells from HIV-infected individuals. Hum Gene Ther 1998;9:487-96.
7. Mhashilkar AM, Biswas DK, LaVecchio J, Pardee AB, Marasco WA. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-B antagonists. J Virol 1997;71:6486-94.
8. Duan L, Bagasra O, Lauglin MA, Oakes JW, Pomerantz RJ. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 1994;91:5075-9.
9. Duan L, Zhu M, Bagasra O, Pomerantz RJ. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments. Hum Gene Ther 1995;6:1561-73.
10. Wu Y, Duan L, Zhu M, et al. Binding of intracellular anti-Rev single-chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition. J Virol 1996;70:3290-7.
11. Levin R, Mhashilkar AM, Dorfman T, et al. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med 1997;3:96-110.
12. Shaheen F, Duan L, Zhu M, Bagasra O, Pomerantz R. Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J Virol 1996;70:3392-400.
13. Maciejewski JP, Weichold F, Young NS, et al. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat Med 1995;1:667-73.
14. Levy-Mintz P, Duan L, Zhang H, et al. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J Virol 1996;70:8821-32.
15. Curiel TJ, Piché A, Kasono K, Curiel DT. Gene therapy strategies for AIDS-related malignancies. Gene Ther 1997;4:1284-8.
16. Gail MH, Pluda JM, Rabkin CS, et al. Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst 1991;83:695-701.
17. Piché A, Kasono K, Johanning F, Curiel TJ, Curiel DT. Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody. Gene Ther 1998;5:1171-9.
18. Chen JD, Bai X, Yang AG, Cong Y, Chen SY. Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat Med 1997;3:1110-6.
19. Cohen EA, Dehni G, Sodroski JG, Haseltine WA. Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 1990;64:3097-9.
20. Yuan X, Matsuda Z, Matsuda M, Essex M, Lee TH. Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses 1990;6:1265-71.
21. Liu H, Wu X, Newman M, Hahn BH, Kappes JC. The vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol 1995;69:7630-8.
22. Heinzinger NK, Bukinsky MI, Haggerty SA, et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nodividing host cells. Proc Natl Acad Sci USA 1994;91:7311-5.
23. Wu X, Liu H, Xiao H, et al. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol 1995;69:3389-98.
24. Wu X, Liu H, Xiao H, Conway JA, Kappes JC. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles. J Virol 1996;70:3378-84.
25. Kobinger GP, Borsetti A, Nie Z, et al. Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion protiens. J Virol 1998;72:5441-8.
26. Serio D, Riziv TA, Cartas M, et al. Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci USA 1997;94:3346-51.
27. Malim MH, Freimuth WW, Liu J, et al. Stable expression of transdominant rev prtoein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 1992;176:1197-201.
28. Liem SE, Ramezani A, Li X, Joshi S. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum Gene Ther 1993;4:625-34.
29. Trono D, Feinberg MB, Baltimore D. HIV-1 gag mutants dominantly interfere with the replication of the wild-type virus. Cell 1989;59:113-20.
30. Buschschacher GL Jr, Freed EO, Panganiban AT. Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus. Hum Gene Ther 1992;3:391-7.
31. Nabel GJ, Fox BA, Post L, Thompson CB, Woffendin C. A molecular genetic intervention for AIDS - effects of a transdominant negative form of Rev. Hum Gene Ther 1994;5:79-92.
32. Ranga U, Woffendin C, Verma S, et al. Enhanced T cells engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci USA 1998;95:1201-6.
33. Bunnell BA, Morgan RA. Gene therapy for AIDS. Mol Cell 1996;1:1-12.
34. Sarver N, Cantin EM, Chang PS, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990;247:1222-5.
35. Yu M, Ojwang J, Yamada O, et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:6340-4.
36. Yamada O, Kraus G, Luznik L, Yu M, Wong-Staal F. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-Ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol 1996;70:1596-601.
37. Gervaix A, Li X, Kraus G, Wong-Staal F. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol 1997;71:3048-53.
38. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
39. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1. Nature 1995;373:117-22.
40. Veres G, Junker U, Baker J, et al. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J Virol 1998;72:1894-901.
41. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences render cells resistant to human immunodeficiency virus replication. Cell 1990;63:601-8.
42. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 1991;65;6811-6.
43. Lee TC, Sullinger BA, Gallardo HF, et al. Overexpression of RRE-derived sequences inhibits HIV-replication in CEM cells. New Biol 1992;4:66-74.
44. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
45. + hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS-virus infection. J Virol 1997;71:2740-6.
46. Joshi S, Ramezani A, Medina MM, et al. RNA and protein based strategies for use in anti-HIV gene therapy. 6th Annual Canadian conference on HIV/AIDS Research. Can J Infect Dis 1997;8:61A. (Abst 407)